Navigation Links
Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets
Date:4/29/2009

SAN CARLOS, Calif., April 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2009 on Wednesday, May 6, 2009, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Wednesday, May 20, 2009.

        To access the conference call, follow these instructions:

        Dial: (888) 396-2369 (U.S.); (617) 847-8710 (international)
        Passcode: 82263149 (Howard Robin is the host)

An audio replay will also be available shortly following the call through Wednesday, May 20, 2009 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 19053055.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. More information on Nektar is available at http://www.nektar.com

                Jennifer Ruddock, 650-631-4954, Nektar Therapeutics


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
2. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
3. Nektar Therapeutics Announces Second Quarter 2008 Results
4. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
5. Nektar Therapeutics Announces First Quarter 2008 Results
6. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
7. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
8. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
10. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
11. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... OAKLAND, CA (PRWEB) , ... January 17, 2017 , ... ... been named winners of the fourth Cradle to Cradle Product Design Challenge , ... the fourth in a series of six circular design challenges scheduled to run through ...
(Date:1/17/2017)... NJ (PRWEB) , ... January 17, 2017 , ... Neil ... and financial planning assistance to communities throughout the region, is launching a charity drive ... Heart disease is by far the deadliest killer in America, and is responsible for ...
(Date:1/17/2017)... ... , ... SC&H Group, a leading audit, tax, and consulting firm, announced that ... Services practice . Rossi is the third technology consulting leader to join SC&H Group’s ... and the practice continues to expand.     , Bringing more than 25 years of business ...
(Date:1/17/2017)... ... 17, 2017 , ... Seceon , the only threat ... today announced a strategic partnership with TechLab Security, a leading Enterprise ... TechLab Security has become a strategic partner and a value added reseller of ...
(Date:1/17/2017)... ... January 17, 2017 , ... The ... in Tyler, has announced the latest beneficiary of their thriving community involvement program. ... organization dedicated to fulfilling the dreams of terminally ill patients. Donations to this ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan 17, 2017 Research and ... Market 2016-2020" report to their offering. ... The global laparotomy sponges market to ... Global Laparotomy Sponges Market 2016-2020, has been prepared ... The report covers the market landscape and its growth prospects over ...
(Date:1/17/2017)... , January 17, 2017 ... 2016;11(Suppl. 1):2-4 ; http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ... ... Published recently in European Neurological ... touchNEUROLOGY, Catherine Amey reports that despite ...
(Date:1/17/2017)... Transparency Market Research has released a new market report ... and Others) Market - Global Industry Analysis, Size, Share, Growth, Trends ... derivative market was valued at US$ 1.37 Bn in 2015 ... at a CAGR of 5.1 % from 2016 to 2024. ... Benzaldehyde derivatives are the ...
Breaking Medicine Technology: